Premium
Carcinoembryonic antigen and phosphohexose isomerase, gammaglutamyl transpeptidase and lactate dehydrogenase levels in patients with and without liver metastases
Author(s) -
Munjal Devidayal,
Chawla Prem L.,
Lokich Jacob J.,
Zamcheck Norman
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197604)37:4<1800::aid-cncr2820370426>3.0.co;2-k
Subject(s) - carcinoembryonic antigen , medicine , lactate dehydrogenase , glucose 6 phosphate isomerase , breast cancer , cancer , lung cancer , malignancy , gastroenterology , pathology , enzyme , biochemistry , biology
Plasma carcinoembryonic antigen (CEA) and serum enzyme levels of phosphohexose isomerase (PHI), gamma‐glutamyl transpeptidase (γ‐GTP), and lactate dehydrogenase (LDH) were measured in 147 patients with malignancy. Levels were higher in patients (particularly with G.I., breast and lung cancers) than in normals or in patients with cancer in clinical remission. Elevations of CEA and of all three enzymes in blood were most frequent in patients with hepatic metastases. CEA elevations correlated directly with PHI levels. Seventy‐eight percent of patients with metastatic G.I. cancer could be identified by CEA (>5 ng/ml) alone, as well as 38% with breast cancer and 85% with lung cancer; but only 17% of other cancers could be identified by CEA alone. CEA or one or more enzymes was elevated in 64% of metastatic breast cancer patients, 92% of lung cancer and 41% of other cancers, but enzyme measurement did not increase identification of G.I. cancer over that achieved by CEA alone. These findings suggest that circulating levels of CEA, PHI, γ‐GTP and LDH may reflect a direct contribution from the malignant tissue and/or liver malfunction secondary to liver replacement.